Assessment of Drug Activities against Giardia Using Hyperspectral Raman Microscopy

Felicia S Manciu1,2, Jose Guerrero1, Breanna C Pence3

  • 1Department of Physics, University of Texas at El Paso, El Paso, TX 79968, USA.

PubMed

Insights

Raman microscopy reveals distinct cellular changes in Giardia cells treated with metronidazole (MTZ) or oseltamivir (OSM). MTZ causes iron-related vesicle release, while OSM impacts cell structure more destructively.

Area of Science:

  • Biochemistry
  • Cell Biology
  • Microscopy

Background:

  • Giardiasis remains a significant public health concern, necessitating novel therapeutic strategies.
  • Understanding drug interactions at the cellular and molecular level is crucial for effective treatment and combating drug resistance.

Purpose of the Study:

  • To investigate the structural and molecular changes in Giardia cells upon exposure to metronidazole (MTZ) and oseltamivir (OSM) using Raman microscopy.
  • To compare the effects of different drugs and incubation times on Giardia cell structures.

Main Methods:

  • Label-free Raman microscopy was employed to analyze structural modifications in Giardia cells.
  • Confocal fluorescence microscopy was used to confirm drug incorporation and impact on cell membranes.

Main Results:

  • Metronidazole (MTZ) induced extracellular vesicle release containing toxic iron intermediates and modified triple-bond moieties, with notable changes in heme protein environment and iron transformation.
  • Oseltamivir (OSM) altered phenylalanine and lipid structures, demonstrating a more destructive impact on the plasma membrane and lipid rafts.
  • Incubation time influenced vesicle content, with shorter exposures showing protein, glycogen, and phospholipid releases, while longer exposures revealed transformed iron complexes.

Conclusions:

  • Raman microscopy offers a powerful tool for label-free, simultaneous monitoring of cellular and molecular changes during drug treatment.
  • The study elucidates multifaceted mechanisms underlying giardiasis treatment and potential drug resistance, highlighting distinct cellular responses to MTZ and OSM.

Related Concept Videos

Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents01:18

Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents

Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
Giardiasis01:12

Giardiasis

Giardiasis is a globally prevalent intestinal infection caused by the protozoan parasite Giardia duodenalis (also known as G. lamblia or G. intestinalis). This flagellated protozoan is the most frequently identified intestinal parasite in the United States and worldwide. Transmission primarily occurs via the fecal-oral route, with infection arising from ingestion of water or food contaminated with cysts. Individuals in low-resource settings, international travelers, outdoor enthusiasts, daycare...
Anthelminthic Agents01:15

Anthelminthic Agents

Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
Antiprotozoal Agents01:21

Antiprotozoal Agents

Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...